325 related articles for article (PubMed ID: 23830194)
1. Nuclear EGFR as a molecular target in cancer.
Brand TM; Iida M; Luthar N; Starr MM; Huppert EJ; Wheeler DL
Radiother Oncol; 2013 Sep; 108(3):370-7. PubMed ID: 23830194
[TBL] [Abstract][Full Text] [Related]
2. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
[TBL] [Abstract][Full Text] [Related]
3. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
4. Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides.
Yu YL; Chou RH; Liang JH; Chang WJ; Su KJ; Tseng YJ; Huang WC; Wang SC; Hung MC
PLoS One; 2013; 8(4):e61362. PubMed ID: 23593472
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
6. A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Box C; Mendiola M; Gowan S; Box GM; Valenti M; Brandon Ade H; Al-Lazikani B; Rogers SJ; Wilkins A; Harrington KJ; Eccles SA
Eur J Cancer; 2013 Jul; 49(11):2512-21. PubMed ID: 23582742
[TBL] [Abstract][Full Text] [Related]
7. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Irwin ME; Mueller KL; Bohin N; Ge Y; Boerner JL
J Cell Physiol; 2011 Sep; 226(9):2316-28. PubMed ID: 21660955
[TBL] [Abstract][Full Text] [Related]
8. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
10. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Wang YC; Kulp SK; Wang D; Yang CC; Sargeant AM; Hung JH; Kashida Y; Yamaguchi M; Chang GD; Chen CS
Cancer Res; 2008 Apr; 68(8):2820-30. PubMed ID: 18413750
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
[TBL] [Abstract][Full Text] [Related]
12. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
13. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
14. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
15. Nuclear EGFR contributes to acquired resistance to cetuximab.
Li C; Iida M; Dunn EF; Ghia AJ; Wheeler DL
Oncogene; 2009 Oct; 28(43):3801-13. PubMed ID: 19684613
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin AR; Müller S; Lewis M; Sica G; Kono S; Brandes JC; Grist WJ; Moreno-Williams R; Beitler JJ; Thomas SM; Chen Z; Shin HJ; Grandis JR; Khuri FR; Chen ZG
Clin Cancer Res; 2013 Mar; 19(5):1244-56. PubMed ID: 23422093
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
[TBL] [Abstract][Full Text] [Related]
18. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
19. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
20. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.
Iida M; Brand TM; Campbell DA; Li C; Wheeler DL
Oncogene; 2013 Feb; 32(6):759-67. PubMed ID: 22430206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]